Autologous hematopoietic stem cell transplantation in multiple sclerosis

Neurology

Volumn 84, Issue 10, 2015, Pages 981-988

  Mancardi, Giovanni L ^a   Sormani, Maria P ^a   Gualandi, Francesca ^b   Saiz, Albert ^c   Carreras, Eric ^c   Merelli, Elisa ^d   Donelli, Amedea ^d   Lugaresi, Alessandra ^e   Di Bartolomeo, Paolo ^f   Rottoli, Maria R ^g   Rambaldi, Alessandro ^h   Amato, Maria P ⁱ   Massacesi, Luca ⁱ   Di Gioia, Massimo ⁱ   Vuolo, Luisa ⁱ   Currò, Daniela ^a   Roccatagliata, Luca ^a   Filippi, Massimo ^j   Aguglia, Umberto ^k   Iacopino, Pasquale ^l   Farge, Dominique ^m   Saccardi, Riccardo ⁱ   more..

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f SPIRITO SANTO HOSPITAL   (Italy)

^g PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^h Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j Division of Neuroscience   (Italy)

^k UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^l NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^m SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FILGRASTIM; GADOLINIUM; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ADULT; AMENORRHEA; ANEMIA; ARTHRITIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITAL DISCHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LEUKOPENIA; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; DIAGNOSTIC USE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMAGE ENHANCEMENT; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; GADOLINIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924368416     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001329     Document Type: Article

References (39)

1. Ikehara S, Good RA, Nakamura T, et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 1985;82:2483-2487.
2. Van Bekkum DW, Bohre EP, Houben PF, Knaan-Shanzer S. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci USA 1989;86: 10090-10094.
3. Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells 1994;12: 125-135.
4. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autolo-gous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005;201:805-816.
5. Alexander T, Thiel A, Rosen O, et al. Depletion of autor-eactive immunologic memory followed by autologous stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009;113:214-223.
6. Muraro PA, Abrahamsson SV. Resetting autoimmunity in the nervous system: the role of hematopoietic stem cell transplantation. Curr Opin Investig Drugs 2010;11: 1265-1275.
7. Darlington P, Touil T, Doucet J, et al. Diminished Th17 (Not Th1) responses underline multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013;73:341-354.
8. Abrahamsson SV, Angelini DF, Dubinsky AN, et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiples sclerosis. Brain 2013;136:2888-2903.
9. Muraro P, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 2014;124:1168-1172.
10. Farge D, Labopin M, Tyndall A, et al. Autologous hema-topoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Hae-matologica 2010;95:284-292.
11. Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47:770-790.
12. Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631-638.
13. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003;102:2364-2372.
14. Saccardi R, Mancardi GL, Solari A, et al. Autologous HSCT for severe progressive multiple sclerosis in a multi-center trial: impact on disease activity and quality of life. Blood 2005;105:2601-2607.
15. Kozák T, Havrdová E, Pit'ha J, et al. High-dose immu-nosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000;25:525-531.
16. Su L, Xu J, Ji BX, et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006;84:276-281.
17. Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autolo-gous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 2006;20: 485-489.
18. Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Autolo-gous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol 2012;40:892-898.
19. Mancardi GL, Murialdo A, Rossi P, et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 2005;11:367-371.
20. Kimiskidis V, Sakellari I, Tsimourtou V, et al. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Mult Scler 2008; 14:278-283.
21. Burman J, Iacobaeus E, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis. The Swedish experience. J Neurol Neu-rosurg 2014;85:1116-1121.
22. Portaccio E, Amato MP, Siracusa G, et al. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. Mult Scler 2007;13:676-678.
23. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
24. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neuro-surg Psychiatry 1997;62:112-118.
25. Mancardi GL, Saccardi R, Filippi M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001;57:62-68.
26. Saiz A, Blanco Y, Carreras E, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 2004;62:282-284.
27. Ory S, Debouverie M, Le Page E, et al. Use of mitoxan-trone in early multiple sclerosis with malignant disease course: observational study in 30 patients with clinical and MRI outcomes after one year. Rev Neurol 2008;164: 1028-1034.
28. Freedman MS, Atkins DL, Arnold A, et al. Immune ablation and autologous stem cell transplantation for aggressive multiple sclerosis: interim 5 year report. Mult Scler 2007; 13:S22. Abstract.
29. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double blind, randomised, multicentre trial. Lancet 2002;360: 2018-2025.
30. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108.
31. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8:244-253.
32. Krasulová E, Trneny M, Kozák T, et al. High-dose im-munoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010;16:685-693.
33. Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011;76:1066-1070.
34. Mancardi GL, Sormani MP, Di Gioia M, et al. Autolo-gous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 2012;18:835-842.
35. Bowen JD, Kraft GH, Wundes A, et al. Autologous hae matopoietic stem cell Transplantation following high-dose immunosuppressive therapy for advanced multiple sclero sis: long-term results. Bone Marrow Transplant 2012;47: 946-951.
36. Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003;102:2373-2378.
37. Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomized trials. Lancet Neurol 2013;12:669-676.
38. Sormani MP, Bonzano L, Roccatagliata L, et al. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology 2010;75:302-309.
39. Saccardi R, Freedman MS, Sormani MP, et al; European Blood and Marrow Transplantation Group, Center for International Blood and Marrow Research, HSCT in MS International Study Group. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler 2012;18:825-834.